SBIR/STTR Research Award
RAPID DIAGNOSTIC FOR CLOSTRIDIUM DIFFICILE TOXIN B
Award amount
$515,460Program and phase
SBIR · Phase IIAward year
1994Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Cambridge Biotech Corp.ora- Ti
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
THE LONG-TERM OBJECTIVE IS TO DEVELOP A RAPID ENZYME LINKED IMMUNOASSAY FOR TOXIGENIC CLOSTRIDIUM DIFFICILE. C. DIFFICILE IS THE MOST FREQUENT CAUSE OF ANTIBIOTIC-ASSOCIATED DIARRHEA AND COLITIS, AND THE MOST FREQUENTLY IDENTIFIED CAUSE OF ENTERIC DISEASE IN INDUSTRIALIZED NATIONS. SINGLE TREATMENT OF PATIENTS WITH VIRTUALLY ANY ANTIBIOTIC CAN INDUCE AN OVERGROWTH OF INTESTINAL MICROFLORA BY C. DIFFICILE AND CAUSE DISEASE. A VERY RELIABLE DIAGNOSTIC PROCEDURE WHICH DETECTS AN EXOTOXIN, TOXIN B, ALREADY EXISTS BUT REQUIRES 48 HOURS TO PERFORM AND A SOPHISTICATED CELL CULTURE FACILITY. ALTHOUGH EFFECTIVE THERAPY EXISTS FOR C. DIFFICILE, IT IS USUALLY WITHHELD UNTIL THE RESULTS OF THE CELLULAR ASSAY ARE KNOWN, BECAUSE A MAJORITY OF SAMPLES ASSAYED LACK TOXIN. AN ALTERNATIVE ASSAY SHOULD REQUIRE LESS TIME WHILE PRESERVING SPECIFICITY FOR TOXIN B. WE HAVE DEVELOPED A PANEL OF MURINE MONOCLONAL ANTIBODIES SPECIFIC FOR TOXIN B, HIGH TITERED TOXIN B SPECIFIC ANTISERA AND PURIFICATION METHODS FOR TOXIN B. THE RESEARCH PLAN WILL MAKE USE OF CONVENTIONAL IMMUNOLOGICAL METHODS TO DEVELOP AN ANTIGEN CAPTURE TEST USING THESE REAGENTS AS WE HAVE PREVIOUSLY DONE WITH ADENOVIRUS AND ROTAVIRUS.
Technology keywords
Not reported